ENTRY       D11035            Mixture   Drug
NAME        Fluticasone furoate, umeclidinium bromide and vilanterol;
            Trelegy ellipta (TN)
PRODUCT     TRELEGY ELLIPTA (GlaxoSmithKline LLC)
COMPONENT   Fluticasone furoate [DR:D06315], Umeclidinium bromide [DR:D10181], (Vilanterol trifenatate [DR:D09697] | Vilanterol [DR:D09696])
REMARK      Therapeutic category: 2290
            ATC code: R03AL08
            Product: D11035<JP/US>
EFFICACY    Bronchodilator
  DISEASE   Chronic obstructive pulmonary disease [DS:H01714]
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             R RESPIRATORY SYSTEM
              R03 DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
               R03A ADRENERGICS, INHALANTS
                R03AL Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
                 R03AL08 Vilanterol, umeclidinium bromide and fluticasone furoate
                  D11035  Fluticasone furoate, umeclidinium bromide and vilanterol &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Respiratory Tract/Pulmonary Agents
              Bronchodilator Combinations
               Fluticasone Furoate/ Umeclidinium/ Vilanterol
                D11035  Fluticasone furoate, umeclidinium bromide and vilanterol
            Therapeutic category of drugs in Japan [BR:br08301]
             2  Agents affecting individual organs
              22  Respiratory organ agents
               229  Miscellaneous
                2290  Miscellaneous
                 D11035  Fluticasone furoate, umeclidinium bromide and vilanterol
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D11035
DBLINKS     PubChem: 350078354
///
